Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Two Biotech Stocks Have Been Ignoring the Crowd Today and This Metric Says They are Poised to Grow Even Further

Page 1 of 2

Amid a broader market sell-off,  several biotechnology stocks have surged in today’s trading session, although the industry overall has declined with the NASDAQ Biotech Index down by almost 3%.  We have previously covered the developments that stood behind today’s gains of Arrowhead Research Corp (NASDAQ:ARWR) and Capnia Inc (NASDAQ:CAPN), and in this article we will discuss on what has been driving up the share prices of two other biotech companies, namely Keryx Biopharmaceuticals (NASDAQ:KERX) and Conatus Pharmaceuticals Inc (NASDAQ:CNAT). At the same time, we will also take a brief look at the hedge funds sentiment on these two stocks in order to assess whether top money managers had faith in the risky biotech companies.

Biotech Stocks 15

Why do we pay attention to hedge fund sentiment? Most investors ignore hedge funds’ moves because as a group their average net returns trailed the market since 2008 by a large margin. Unfortunately, most investors don’t realize that hedge funds are hedged and they also charge an arm and a leg, so they are likely to underperform the market in a bull market. We ignore their short positions and by imitating hedge funds’ stock picks independently, we don’t have to pay them a dime. Our research has shown that hedge funds’ long stock picks generate strong risk-adjusted returns. For instance, the 15 most popular small-cap stocks outperformed the S&P 500 Index by an average of 95 basis points per month in our backtests spanning the 1999 – 2012 period. We have been tracking the performance of these stocks in real-time since the end of August 2012. After all, things change and we need to verify that back-test results aren’t just a statistical fluke. We weren’t proven wrong. These 15 stocks managed to return more than 118% over the last 36 months and outperformed the S&P 500 Index by 60 percentage points (see more details here).

Going back to today’s biotech winners, Keryx Biopharmaceuticals (NASDAQ:KERX) announced earlier this morning that the European Commission had approved its drug Fexeric for the control of high serum phosphorus levels in patients with chronic kidney disease (CKD), including both dialysis and pre-dialysis patients. It is worth mentioning that Fexeric was also approved by the U.S. FDA back in 2014 under the Auryxia brand name; however, the drug is indicated only for the patients with CKD on dialysis. Moving on to the potential gains from the freshly-announced approval, the company stated in a press release that there are approximately 1.3 million people diagnosed with CKD in five biggest markets in Europe, 750,000 of whom are estimated to have hyperphosphatemia. The market potential in Europe is way larger than in the U.S., where the drug is indicated for only 450,000 people with hyperphosphatemia and end-stage renal disease who require dialysis, the statement added. The stock opened sharply higher but is currently up by less than 2% and it still has lost over 70% since the beginning of 2015.

Follow Keryx Biopharmaceuticals Inc (NASDAQ:KERX)
Trade (NASDAQ:KERX) Now!

Keryx Biopharmaceuticals (NASDAQ:KERX) lost some charm among the hedge funds tracked by Insider Monkey, with 18 investors holding shares at the end of the second quarter, compared to 23 a quarter earlier. Similarly, the value of hedge funds’ holdings in Keryx decreased to $325.25 million from $457.84 million. Nevertheles, these 18 hedge funds owned approximately 31.60% of the company’s outstanding shares at the end of June. Seth Klarman’s Baupost Group is by far the largest shareholder of Keryx within our database, owning 25.79 million shares.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!